FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)

View source ↗

Summary

FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Giant Cell Arteritis
• Juvenile Idiopathic Arthritis
• Polyarticular Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• AVTOZMA (TOCILIZUMAB)

Snippet

SUPPL AP for AVTOZMA (TOCILIZUMAB)